Canton Strategic Holdings (CNTN) EBITDA (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly EBITDA came in at -$36.9 million in Q1 2026, down 1347.71% YoY from $3.0 million in Q1 2025, and down 170.8% on a QoQ basis from -$13.6 million in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) EBITDA (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of EBITDA data on file, last reported at -$36.9 million in Q1 2026.
- Quarterly EBITDA fell 1347.71% year-over-year to -$36.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.4 million (down 331.99% YoY) and the FY2025 annual result came in at -$20.1 million, down 62.15% from the prior year.
- EBITDA eased to -$36.9 million in Q1 2026, from -$13.6 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$1.4 million in Q1 2022 to a low of -$36.9 million in Q1 2026.
- A 5-year average of -$5.0 million and a median of -$2.4 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA slumped 1638.74% — and 2025, when it jumped 45.84%.
- Tracing CNTN's EBITDA over 5 years: stood at -$1.8 million in 2022, then plunged by 43.29% to -$2.5 million in 2023, then slumped by 50.67% to -$3.8 million in 2024, then sank by 257.0% to -$13.6 million in 2025, then slumped by 170.8% to -$36.9 million in 2026.
- The last three EBITDA figures came in at -$36.9 million (Q1 2026), -$13.6 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | -1.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.20 Mn |
| Mar 31, 2026 | -36.87 Mn |
| Dec 31, 2025 | -13.61 Mn |
| Sep 30, 2025 | -2.09 Mn |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | -2.55 Mn |
| Dec 31, 2024 | -3.85 Mn |
| Sep 30, 2024 | -3.87 Mn |
| Jun 30, 2024 | -2.37 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | -2.53 Mn |
| Sep 30, 2023 | -1.85 Mn |
| Jun 30, 2023 | -2.36 Mn |
| Mar 31, 2023 | -2.71 Mn |
| Dec 31, 2022 | -1.77 Mn |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Dec 31, 2021 | -101,593.00 |
| Sep 30, 2021 | -541,113.00 |